Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

rally inhaled acute migraine medication in development which has a multi-targeted mechanism of action, utilizes the company's proprietary TEMPO(R) inhaler and is designed to optimize the key characteristics of dihydroergotamine, an active ingredient which has been used to effectively and safely treat migraines for over 60 years. MAP0004 has the potential to provide a faster onset of action than currently available migraine treatments, with sustained pain relief and pain freedom, in an easy-to-use, non-invasive, at-home therapy. In a Phase 2 clinical trial, patients reported pain relief in as fast as 10 minutes, with sustained relief to 24 and 48 hours. The safety data generated to date have shown MAP0004 to be well tolerated with no significant adverse events reported.

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States, according to the National Headache Foundation (NHF). Common symptoms include recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. According to the NHF, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technolo
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... its potential to revolutionize the world has attracted ... corporations and small start-ups. The early years of ... projects largely due to the high risks involved, ... budgets earmarked for this evolving technology have been ...
(Date:9/19/2014)... SAN FRANCISCO , Sept. 19, 2014 /PRNewswire/ ... announced results from preclinical studies characterizing the analgesic ... oral, peripherally-acting kappa opioid receptor agonist molecules. The ... molecule polymer medicinal chemistry platform. The ... described in the medical literature. 1,2 Kappa ...
(Date:9/19/2014)... NC (PRWEB) September 19, 2014 ... Biobased Product Label for its Organic Cotton . ... product’s amount of renewable biobased ingredients meets or exceeds ... intermediate materials composed in whole or in significant part ... logo/label will allow our Organic cotton to be immediately ...
(Date:9/19/2014)... , The first grants awarded ... Endocrinology (ESPE) Meeting  Investment supports innovative projects ... the field of growth  , EMD Serono, ... , today announced the first recipients of the ... were announced during a Satellite Symposium organized by EMD ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... , , SAN DIEGO , ... BMR ) today announced the signing of an amendment to its ... 301 Binney Street laboratory research facility in Cambridge, Massachusetts . ... laboratory and office space contiguous to its existing premises located in ...
... , , ... Reportlinker.com announces that a new market research ... The Future of Nutrigenomics: New opportunities in ... http://www.reportlinker.com/p0177850/The-Future-of-Nutrigenomics-New-opportunities-in-personalized-nutrition-and-food-pharma-collaboration.html , Nutrigenomics explores how nutrients ...
... , CRANBURY, N.J. , Feb. 16 ... for its second quarter ended December 31, 2009 .  Palatin reported net ... diluted share, for the quarter ended December 31, 2009 , compared to ... basic and diluted share, for the same period in 2008.  Total revenues in ...
Cached Biology Technology:BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 2BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 3BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 2Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 3Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 5Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 6Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 2Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 3Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 4Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 5Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 6Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 7
(Date:9/17/2014)... atmospheric scientists were instrumental in the creation of the ... to classify the fire threat potential of the powerful, ... spark into an inferno. The index was introduced Sept. ... UCLA and San Diego Gas and Electric. , The ... "extreme" that will be used to help fire agencies ...
(Date:9/17/2014)... engineering professor and his doctoral student have designed a ... water collected from fog and dew., The device could ... deserts around the globe., Cheng Luo, professor in the ... candidate in the same College of Engineering department, published ... of ACS, (American Chemical Society) Applied Materials ...
(Date:9/17/2014)... 17, 2014) A rare genetic disorder known as Jacobsen ... recent joint investigation by researchers at San Diego State ... addition to suggesting better treatment options for people with ... the genetic underpinnings of autism., Jacobsen syndrome affects approximately ... of Health. It occurs in a person when there ...
Breaking Biology News(10 mins):UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Shorebird's beak inspires UT Arlington research on water collection 2A link between Jacobsen syndrome and autism 2
... cells in the eye receptive to light is missing in ... animals like birds, fish and amphibians have two versions of ... The findings ?published in the Public Library of Science journal ... may be impoverished compared to other vertebrates and fits with ...
... Waiting a day or more to get lab results back ... a past. Using nanotechnology, a team of University of Georgia ... as diverse as influenza, HIV and RSV in 60 seconds ... ?which is detailed in the November issue of the journal ...
... 12, 2006 -- A new study in Journal of the ... over smaller shrimp of the same gender when competing for ... though adult males of the species are typically much smaller ... size and gender are important factors in acquiring food," says ...
Cached Biology News:Does missing gene point to nocturnal existence for early mammals? 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 2Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses 3
... NightOWL is a dedicated imaging system ... size. Equipped with a very sensitive camera ... or plants in tumor research, infectious disease ... Western blots. NightOWL is the only imager ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: